Frontline Success Bolsters IO ‘Backbone’ Hopes For GSK’s Jemperli
Also Rivals Keytruda In First-Line NSCLC
Executive Summary
GSK’s PD-1 inhibitor will not be able to make up much ground on Keytruda, but new studies suggest it is a match for the market-leading PD-1 inhibitors.